Skip to main content

Merck's (MRK) KEYTRUDA Receives FDA Breakthrough Therapy Designation from U.S. FDA

Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA.
http://www.streetinsider.com/Corporate+News/Mercks+(MRK)+KEYTRUDA+Receives+FDA+Breakthrough+Therapy+Designation+from+U.S.+FDA/11022966.html

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2023 Esophageal Cancer Education Foundation- by domino